参考文献: Banerjee S, et al. Safety and efficacy results in patients who received dose modifications in the phase 3 MIRASOL (GOG 3045/ENGOT-ov55) trial of mirvetuximab soravtansine vs investigator’s choice chemotherapy (ICC) in platinum-resistant ovarian cancer (PROC) with high folate recep...
1. Konecny GE, Moore KN, Lebreton C, et al. Patient-reported outcome results from phase III MIRASOL trial of mirvetuximab soravtansine versus investigator's choice of chemotherapy in FRα-positive, platinum-resistant ovarian cancer. Presented at: Society of Gynecologic Oncology 2024 Annual Meet...
2024年ESMO妇科癌症大会(ESMO Gynaecological Cancers Congress 2024)于6月20-22日在佛罗伦萨举行。根据这项会议的报道,在叶酸受体α(FRalpha)高、铂耐药卵巢癌患者中进行的III期MIRASOL(GOG3045/ENGOT-ov55)试验的事后分析显示,与研究者选...
doi:10.1016/j.annonc.2024.08.807L. Gardner CoffmanB. YouE.P. HamiltonY. Garcia GarciaK.N. MooreD. SonnenburgG. ScambiaS. DerioJ. Thomes PepinD. Klasa-MazurkiewiczAnnals of Oncology
Clinical trial information: NCT04209855. Research Sponsor: ImmunoGen. 林仲秋教授点评: 铂耐药复发卵巢癌的治疗非常棘手。不论是用非铂药物或再用回铂,大多数药物的ORR都在20%左右。抗体偶联药物(ADC)是一类有希望的新靶向药物,能克服传统化疗药...
Banerjee S, et al. Safety and efficacy results in patients who received dose modifications in the phase 3 MIRASOL (GOG 3045/ENGOT-ov55) trial of mirvetuximab soravtansine vs investigator’s choice chemotherapy (ICC) in platinum-resistant ovarian cancer (PROC) with high folate receptor-alpha ...
Section 2.Order for partition, and partition by agreement thereunder.- If after the trial the court finds that the plaintiff has the right thereto, it shall order the partition of the real estate among all the parties in interest.Thereupon the parties may, if they are able to agree, make ...
In a recent issue of TRANSFUSION, The Mirasol Clinical Evaluation Study Group conducted a multicenter, open-label, parallel-group, noninferiority, randomized clinical trial and reported that "noninferiority could not be claimed" for Mirasol pathogen-reduced platelets (PRT-PLTs; i.e., treated with ...
Nicoletta ColomboEuropean Institute of Oncology IRCCS, University of Milan-Bicocca, Milan, ItalyDavid O'MalleyThe Ohio State University, Columbus, OH, United StatesLan CoffmanUniversity of Pittsburgh Medical Center, Magee-Women's Hospital, Pittsburgh, PA, United States...
Importantly, MIRV had fewer dose discontinuations than ICC, suggesting that TEAEs were more manageable The efficacy data and the well-characterized safety profile support MIRV as the standard of care for pts with FRα positive PROC across all ages.Clinical trial information: NCT04209855.Diana Bello...